biotechnology

Enveric Biosciences Inc (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogen therapeutics for mental health conditions, has entered into a licensing agreement with MycoMedica Life Sciences. Enveric will out-license its EVM201 program, including the drug candidate EB-002 (formerly...

Biotechnology company Illumina, Inc. (NASDAQ: ILMN) initiated layoffs within its research and development (R&D) team, affecting approximately 10% of that staff. These layoffs began late last Wednesday and impacted research teams at various locations, including San Diego and Foster...

Shares of ImmunityBio (NASDAQ: IBRX) were down 55.1% on Thursday after management announced that FDA issued a complete response letter ("CRL") to its biologics license application ("BLA") seeking approval for the combination use of its lead pipeline candidate, Anktiva (N-...

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune response-triggered maladies. The company went public in December 2020. Shares reached a high of $16.71 before making...

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. For the purpose of this article, Benzinga will delve into the Bill & Melinda Gates Foundation which is heavily concentrated in biotechnology and health...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Investors often see pharma and biotech stocks as reliable havens at times of volatility. But while the Covid pandemic has brought some...

Shares of bluebird bio Inc. (NASDAQ: BLUE) surged over 13 percent last week as the company announced plans to release abstracts at the American Society of Hematology meeting in December. The Analyst Janney analyst Yun Zhong upgraded bluebird from Neutral to Buy and maintained a $170 price...

Equillium is set to begin trading on the Nasdaq Global Market under the ticker symbol “EQ.” The Details Equillium will offer 4.6 million shares of common stock in a price range between $14 and $16 per share. The company intends to raise $70 million, according to the S-1 filing. At the...

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA), a biotechnology company developing GalXC RNAi platforms for various diseases, has seen its stock soar 140 percent over the past six months. But a combination of good news and bad news should leave investors on the sidelines, according to B. Riley FBR....

Multiple small- and mid-cap biotech stocks have benefited from a strong run, prompting Morgan Stanley to downgrade three companies in the group. The Analyst Morgan Stanley's Matthew Harrison downgraded the following: Sarepta Therapeutics Inc (NASDAQ: SRPT) from Overweight to Sector Weight...

Shares of bluebird bio Inc (NASDAQ: BLUE) gained more than 200 percent in value last year and investors can expect 2018 to be another "blue-ribbon year" for the stock, according to William Blair. The Analyst Willaim Blair's Raju Prasad initiated coverage of bluebird bio's...

Few would call the biotech sector as exciting as the "FAANG" group. But throughout 2017, investors who completely ignored biotech stocks missed out on strong gains. The Nasdaq Biotechnology index outperformed the S&P 500 index throughout the year. The Analyst Bank of America...

Biotech stocks are off to a rough start on Thursday, especially Celgene Corporation (NASDAQ: CELG), as shares plummeted to a new 52-week low of $95.50. Celgene reported Wednesday mixed third-quarter results, but investors appear to be fixated on the company's 2020 guidance update. The company...

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) gained 10 percent on Thursday in reaction to the company's encouraging update to a phase 2 trial of its autoimmune disease drug called anabasum. Corbus' top-line data from a 22-patient study of anabasum for the treatment of...

Shares of Endocyte, Inc. (NASDAQ: ECYT) were trading higher by more than 60 percent Tuesday afternoon at $5.82 on top of Monday's monster triple-digit-percentage return gain, but some analysts see even more upside. Wedbush's David Nierengarten upgraded Endocyte's stock rating Neutral to Outperform...